Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer

Identifieur interne : 001271 ( Main/Exploration ); précédent : 001270; suivant : 001272

Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer

Auteurs : Yuan-Yuan Li [Hong Kong] ; Sze-Kwan Lam [Hong Kong] ; Judith Choi-Wo Mak [Hong Kong] ; Chun-Yan Zheng [Hong Kong] ; James Chung-Man Ho [Hong Kong]

Source :

RBID : Pascal:13-0291630

Descripteurs français

English descriptors

Abstract

Purpose: Erlotinib is a commonly used tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC). Autophagy is a catabolic process in response to stress and deprivation of nutrients. This study aims to investigate whether autophagy confers acquired resistance to erlotinib treatment in NSCLC. Methods: Four NSCLC cell lines (HCC827, HCC4006, H358 and H1975) with different epidermal growth factor receptor (EGFR) mutation status (exon 19 deletion, exon 19 deletion, wild-type and L858R/T790M respectively) were selected. MTT assay, crystal violet staining and Annexin-V assay were performed to determine cell viability and apoptosis. Autophagic proteins were detected by Western blot. Acidic vesicular organelle (AVO) formation was determined by acridine orange staining. Autophagy inhibitor (chloroquine) and RNA interference were used to demonstrate the biological effect of erlotinib-induced autophagy. Results: In line with EGFR mutation status, it was shown that both HCC827 and HCC4006 cells were sensitive to erlotinib, while H358 and H1975 cell lines were resistant. Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression. Addition of chloroquine, as an autophagy inhibitor, enhanced erlotinib sensitivity in sensitive cells. Similarly, silencing of Atg5 or Beclin-1 significantly increased sensitivity to erlotinib in both sensitive cell lines. In contrast, there was no induction of autophagy in resistant H358 and H1975 cell lines upon erlotinib exposure. Conclusions: Erlotinib can induce both apoptosis and autophagy in sensitive NSCLC cell lines with activating EGFR mutation (exon 19 del). Inhibition of autophagy can further enhance sensitivity to erlotinib in EGFR-mutated NSCLC, suggesting that autophagy may serve as a protective mechanism.


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer</title>
<author>
<name sortKey="Li, Yuan Yuan" sort="Li, Yuan Yuan" uniqKey="Li Y" first="Yuan-Yuan" last="Li">Yuan-Yuan Li</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
<wicri:noRegion>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Lam, Sze Kwan" sort="Lam, Sze Kwan" uniqKey="Lam S" first="Sze-Kwan" last="Lam">Sze-Kwan Lam</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
<wicri:noRegion>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Mak, Judith Choi Wo" sort="Mak, Judith Choi Wo" uniqKey="Mak J" first="Judith Choi-Wo" last="Mak">Judith Choi-Wo Mak</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
<wicri:noRegion>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Zheng, Chun Yan" sort="Zheng, Chun Yan" uniqKey="Zheng C" first="Chun-Yan" last="Zheng">Chun-Yan Zheng</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
<wicri:noRegion>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Ho, James Chung Man" sort="Ho, James Chung Man" uniqKey="Ho J" first="James Chung-Man" last="Ho">James Chung-Man Ho</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
<wicri:noRegion>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">13-0291630</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0291630 INIST</idno>
<idno type="RBID">Pascal:13-0291630</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000003</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000063</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000004</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000004</idno>
<idno type="wicri:doubleKey">0169-5002:2013:Li Y:erlotinib:induced:autophagy</idno>
<idno type="wicri:Area/Main/Merge">001272</idno>
<idno type="wicri:Area/Main/Curation">001271</idno>
<idno type="wicri:Area/Main/Exploration">001271</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer</title>
<author>
<name sortKey="Li, Yuan Yuan" sort="Li, Yuan Yuan" uniqKey="Li Y" first="Yuan-Yuan" last="Li">Yuan-Yuan Li</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
<wicri:noRegion>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Lam, Sze Kwan" sort="Lam, Sze Kwan" uniqKey="Lam S" first="Sze-Kwan" last="Lam">Sze-Kwan Lam</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
<wicri:noRegion>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Mak, Judith Choi Wo" sort="Mak, Judith Choi Wo" uniqKey="Mak J" first="Judith Choi-Wo" last="Mak">Judith Choi-Wo Mak</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
<wicri:noRegion>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Zheng, Chun Yan" sort="Zheng, Chun Yan" uniqKey="Zheng C" first="Chun-Yan" last="Zheng">Chun-Yan Zheng</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
<wicri:noRegion>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Ho, James Chung Man" sort="Ho, James Chung Man" uniqKey="Ho J" first="James Chung-Man" last="Ho">James Chung-Man Ho</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</s1>
<s3>HKG</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Hong Kong</country>
<wicri:noRegion>Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Lung cancer</title>
<title level="j" type="abbreviated">Lung cancer</title>
<idno type="ISSN">0169-5002</idno>
<imprint>
<date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Lung cancer</title>
<title level="j" type="abbreviated">Lung cancer</title>
<idno type="ISSN">0169-5002</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Epidermal growth factor receptor</term>
<term>Erlotinib</term>
<term>Lung cancer</term>
<term>Resistance</term>
<term>Respiratory disease</term>
<term>non-small cell lung carcinoma</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Carcinome non petite cellule bronchopulmonaire</term>
<term>Cancer du poumon</term>
<term>Pathologie de l'appareil respiratoire</term>
<term>Erlotinib</term>
<term>Récepteur facteur croissance épiderme</term>
<term>Résistance</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Purpose: Erlotinib is a commonly used tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC). Autophagy is a catabolic process in response to stress and deprivation of nutrients. This study aims to investigate whether autophagy confers acquired resistance to erlotinib treatment in NSCLC. Methods: Four NSCLC cell lines (HCC827, HCC4006, H358 and H1975) with different epidermal growth factor receptor (EGFR) mutation status (exon 19 deletion, exon 19 deletion, wild-type and L858R/T790M respectively) were selected. MTT assay, crystal violet staining and Annexin-V assay were performed to determine cell viability and apoptosis. Autophagic proteins were detected by Western blot. Acidic vesicular organelle (AVO) formation was determined by acridine orange staining. Autophagy inhibitor (chloroquine) and RNA interference were used to demonstrate the biological effect of erlotinib-induced autophagy. Results: In line with EGFR mutation status, it was shown that both HCC827 and HCC4006 cells were sensitive to erlotinib, while H358 and H1975 cell lines were resistant. Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression. Addition of chloroquine, as an autophagy inhibitor, enhanced erlotinib sensitivity in sensitive cells. Similarly, silencing of Atg5 or Beclin-1 significantly increased sensitivity to erlotinib in both sensitive cell lines. In contrast, there was no induction of autophagy in resistant H358 and H1975 cell lines upon erlotinib exposure. Conclusions: Erlotinib can induce both apoptosis and autophagy in sensitive NSCLC cell lines with activating EGFR mutation (exon 19 del). Inhibition of autophagy can further enhance sensitivity to erlotinib in EGFR-mutated NSCLC, suggesting that autophagy may serve as a protective mechanism.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Hong Kong</li>
</country>
</list>
<tree>
<country name="Hong Kong">
<noRegion>
<name sortKey="Li, Yuan Yuan" sort="Li, Yuan Yuan" uniqKey="Li Y" first="Yuan-Yuan" last="Li">Yuan-Yuan Li</name>
</noRegion>
<name sortKey="Ho, James Chung Man" sort="Ho, James Chung Man" uniqKey="Ho J" first="James Chung-Man" last="Ho">James Chung-Man Ho</name>
<name sortKey="Lam, Sze Kwan" sort="Lam, Sze Kwan" uniqKey="Lam S" first="Sze-Kwan" last="Lam">Sze-Kwan Lam</name>
<name sortKey="Mak, Judith Choi Wo" sort="Mak, Judith Choi Wo" uniqKey="Mak J" first="Judith Choi-Wo" last="Mak">Judith Choi-Wo Mak</name>
<name sortKey="Zheng, Chun Yan" sort="Zheng, Chun Yan" uniqKey="Zheng C" first="Chun-Yan" last="Zheng">Chun-Yan Zheng</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001271 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001271 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:13-0291630
   |texte=   Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021